Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 3c, provides guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $44.2 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2024 revenue of $200-220 million, versus the consensus of $219.1 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Evogene (EVGN) Tops Q2 EPS by 15c